Immedica Acquires Marinus Pharmaceuticals for $151M, Expanding Rare Disease Portfolio with ZTALMY
Key Insights
Swedish rare disease specialist Immedica Pharma (search) has agreed to acquire Marinus Pharmaceuticals for $151M, strengthening its position in the global rare disease market through a cash tender offer of $0.55 per share.
The acquisition includes ZTALMY (ganaxolone), an FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (search) in patients aged two and above, marking Immedica's expansion into the US market.
The transaction, unanimously approved by Marinus' board of directors, is expected to close in Q1 2025 and will accelerate Immedica's revenue growth through immediate access to a commercial-stage asset.
Immedica Pharma (search), a global rare disease company based in Stockholm, has entered into a definitive agreement to acquire US-based Marinus Pharmaceuticals in a deal valued at approximately $151 million. The strategic acquisition will significantly expand Immedica's footprint in the rare disease market and establish a strong presence in North America.
Under the terms of the agreement, Immedica will initiate a cash tender offer through its wholly-owned subsidiary to purchase all outstanding shares of Marinus at $0.55 per share. The transaction has received unanimous approval from Marinus' board of directors, who have recommended stockholders tender their shares.
Strategic Addition of ZTALMY to Portfolio
A key asset in the acquisition is ZTALMY (ganaxolone), Marinus' FDA-approved oral suspension for treating seizures associated with CDKL5 deficiency disorder (search) (CDD) in patients two years and older. ZTALMY, approved by the FDA in March 2022, is a neuroactive steroid that acts as a positive modulator of the GABA-A receptor (search).
The addition of ZTALMY represents a significant milestone for Immedica, providing an immediate revenue-generating product in the US market. The drug's unique mechanism of action and approved indication for a rare genetic disorder align well with Immedica's focus on addressing unmet needs in rare diseases.
Expanding Global Presence
"The acquisition of Marinus represents a transformative step in Immedica's journey to further strengthen our position as a leading rare disease company," stated Anders Edvell, CEO of Immedica. "By adding ZTALMY to our portfolio, we significantly strengthen our capabilities and expand our presence in the US, marking a new chapter in our mission to deliver impactful therapies for underserved patient populations."
The transaction provides Immedica with an established commercial team in the United States, accelerating its North American market entry. This expansion aligns with the company's strategic goals to build a global presence in the rare disease space.
Transaction Details and Timeline
Backed by investment companies KKR and Impilo, Immedica currently employs approximately 130 people across Europe, the Middle East, and the US. The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions and regulatory approvals.
The deal structure allows Immedica to leverage Marinus' existing commercial infrastructure while potentially expanding ZTALMY's reach to additional markets worldwide. This strategic move reinforces Immedica's commitment to developing and commercializing treatments for rare diseases and specialty care products.